argenx down as FDA identifies possible safety signal with Vyvgart Hytrulo

 

• argenx (NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).
• The agency says that the treatment, used for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" based on reports to the FDA Adverse Event Reporting System.
• The FDA noted it is evaluating the need for possible regulatory action. 

https://www.msn.com/en-us/money/markets/argenx-down-7-as-fda-identifies-possible-safety-signal-with-vyvgart-hytrulo/ar-AA1HHN2X